Advertisement
Screener

SELLAS Life Sciences Group, Inc. (SLS) Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31)

1.5 / 5 stars · 20/67 Roast Me

SELLAS Life Sciences Group, Inc. Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31)

SELLAS Life Sciences Group, Inc. (SLS) reported Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31) of -$1.05 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-17.

Discontinued › Expense Statement › Income Tax

us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax · last filed 2014-03-17

  • SELLAS Life Sciences Group, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2013-01-31) for the quarter ending 2013-12-31 was -$409.00K.
  • SELLAS Life Sciences Group, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2013-01-31) for the quarter ending 2013-09-30 was -$330.00K.
  • SELLAS Life Sciences Group, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2013-01-31) for the quarter ending 2013-06-30 was -$312.00K.
  • SELLAS Life Sciences Group, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was -$1.00K.
  • SELLAS Life Sciences Group, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2013-01-31) for fiscal 2013 was -$1.05M.
  • SELLAS Life Sciences Group, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2013-01-31) for fiscal 2012 was $0.00.
  • SELLAS Life Sciences Group, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2013-01-31) for fiscal 2011 was $0.00.
Period endOther Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31) 3 monthOther Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31) 6 monthOther Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31) 9 monthOther Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31) 12 monthOther Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31) 126 month
2013-12-31-$409.00K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2014-03-17
-$739.00K
derived: sum of 2 quarters · filed 2014-03-17
-$1.05M
derived: sum of 3 quarters · filed 2014-03-17
-$1.05M
10-K · filed 2014-03-17
2013-09-30-$330.00K
10-Q/A · filed 2013-11-07
-$642.00K
derived: sum of 2 quarters · filed 2013-11-07
-$643.00K
10-Q/A · filed 2013-11-07
-$643.00K
derived: sum of 4 quarters · filed 2014-03-17
2013-06-30-$312.00K
10-Q · filed 2013-08-09
-$312.00K
10-Q · filed 2013-08-09
-$313.00K
derived: sum of 3 quarters · filed 2014-03-17
-$313.00K
derived: sum of 4 quarters · filed 2014-03-17
-$312.00K
10-Q · filed 2013-08-09
2013-03-31-$1.00K
derived: 10-K 12 month − 3 quarters · filed 2014-03-17
-$1.00K
derived: sum of 2 quarters · filed 2014-03-17
-$1.00K
derived: sum of 3 quarters · filed 2014-03-17
-$1.00K
derived: sum of 4 quarters · filed 2014-03-17
2012-12-31$0.00
derived: 10-K 12 month − 10-Q/A 9 month · filed 2014-03-17
$0.00
derived: sum of 2 quarters · filed 2014-03-17
$0.00
derived: sum of 3 quarters · filed 2014-03-17
$0.00
10-K · filed 2014-03-17
2012-09-30$0.00
10-Q/A · filed 2013-11-07
$0.00
derived: sum of 2 quarters · filed 2013-11-07
$0.00
10-Q/A · filed 2013-11-07
2012-06-30$0.00
10-Q · filed 2013-08-09
$0.00
10-Q · filed 2013-08-09
2011-12-31$0.00
10-K · filed 2014-03-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Immunome Inc. (IMNM)United States$2.538B-9.45
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Zai Lab Ltd (ZLAB)$2.241B-113.34